Published in J Urol on September 17, 2007
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci U S A (2012) 2.61
Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol (2012) 1.69
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (2011) 1.40
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer (2009) 1.33
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol (2013) 1.23
Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep (2011) 1.14
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther (2009) 1.07
Update on systemic therapies of metastatic renal cell carcinoma. World J Urol (2010) 1.05
Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer (2013) 1.00
Treatment selection for patients with metastatic renal cell carcinoma. Cancer (2009) 0.99
The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia (2012) 0.99
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer (2009) 0.94
Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Can Urol Assoc J (2014) 0.93
Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2012) 0.93
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Isolated gastric metastasis from renal cell carcinoma 19 years after radical nephrectomy. Int J Clin Oncol (2010) 0.91
Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw (2011) 0.91
Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection. BJU Int (2008) 0.91
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer (2014) 0.89
Metastatic gastric tumors arising from renal cell carcinoma: Clinical characteristics and outcomes of this uncommon disease. Oncol Lett (2012) 0.89
Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma. Front Oncol (2012) 0.88
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs (2013) 0.88
Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am (2011) 0.87
Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia (2012) 0.86
Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol (2010) 0.86
Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opin Drug Discov (2008) 0.85
VEGF and pleiotrophin modulate the immune profile of breast cancer. Cancers (Basel) (2010) 0.84
Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. Cancer Res Treat (2010) 0.83
RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. AJR Am J Roentgenol (2015) 0.81
Kidney cancer pathology in the new context of targeted therapy. Pathobiology (2011) 0.81
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol (2010) 0.81
Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. Neoplasia (2011) 0.79
Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis. Exp Ther Med (2015) 0.78
Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea. Korean J Urol (2010) 0.77
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. Invest New Drugs (2013) 0.77
Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy. Mol Cancer Ther (2016) 0.77
Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC. Nat Rev Clin Oncol (2010) 0.77
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol (2011) 0.76
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications. Ther Adv Med Oncol (2013) 0.75
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist (2016) 0.75
Therapeutic challenges in advanced renal cell carcinoma. Clin Pract (Lond) (2013) 0.75
Metastatic Renal Cell Carcinoma Presenting as a Paranasal Sinus Mass: The Importance of Differential Diagnosis. Case Rep Otolaryngol (2017) 0.75
Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib. Onco Targets Ther (2015) 0.75
State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol (2009) 0.75
Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data. Front Oncol (2015) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res (2011) 3.25
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.69
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol (2012) 2.56
Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Therapy-induced senescence in cancer. J Natl Cancer Inst (2010) 2.45
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 2.25
Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol (2003) 2.22
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology (2009) 2.09
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res (2008) 1.94
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol (2009) 1.85
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol (2003) 1.70
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol (2009) 1.67
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2002) 1.67
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) (2010) 1.66
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol (2010) 1.66
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66